Opinion|Videos|May 9, 2024
Potential Novel Schizophrenia Treatments
A comprehensive discussion on new treatment options for patients with schizophrenia, highlighting the potential for earlier intervention to optimize treatment outcomes.
Advertisement
Episodes in this series
Advertisement
Related to this article
Once-monthly subcutaneous olanzapine TEV-749 shows sustained stabilization and remission in schizophrenia, supports direct switching, and avoids post-injection monitoring.
Real-world data links once-monthly Uzedy to fewer ER visits, better adherence, and lower costs—plus fewer bipolar I relapses when switching from pills.
Despite previous failure of PDE10A inhibitor drugs to demonstrate antipsychotic effects in clinical trials, a new "improved" iteration has met phase 2 trial endpoints.
Study finds most teens with first-episode psychosis stop antipsychotics within a year, boosting ER use; outpatient care and injectables may help.
Experts highlight biomarker-driven schizophrenia care—computational subtypes, muscarinic drugs, sharper negative-symptom scoring, and KCC2 targets—reducing trial-and-error prescribing.
Panelists explain why precision tools lag in schizophrenia care and highlight simple biomarkers, faster deals, and clinician-industry collaboration.
Can hormones flag suicide risk in schizophrenia? Review links cortisol, thyroid and testosterone shifts—and clozapine/lithium pathways—to risk.
RADIANT phase 2 shows once-daily remlifanserin eases Alzheimer’s psychosis symptoms with placebo-like safety, advancing pivotal trials.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Real-World Data Link LAI Risperidone to Fewer Emergency Visits in Schizophrenia, Improved Bipolar Treatment
2
Nature vs Nurture: The Interplay Between Genetics and Environmental Influences
3
Psychedelics as a Catalyst for Change: The Evolving Competitive Landscape in Depression
4
ACNP Position Paper Lays Out Roadmap for Biomarker-Guided Psychiatric Drug Trials
5